Gene Therapeutic Strategies for Peripheral Artery Disease and New Opportunities Provided by Adeno-Associated Virus Vectors

Peripheral artery disease (PAD) is a vascular disorder caused by occlusive atherosclerosis, which commonly impairs blood flow to the lower extremities. The prevalence of PAD is increasing globally with >200 million people affected. PAD remains a growing global health problem as the population continues to age and diabetes incidence grows. Many patients with PAD, most notably those with critical limb ischemia, fail attempts at surgical and percutaneous intervention to improve blood flow and are at risk of amputation. Gene therapy provides an opportunity to change the clinical course of PAD in these patients via strategies that increase vascular supply through angiogenesis and arteriogenesis improving muscle perfusion and function in ischemic legs. This article discusses gene therapy approaches in the context of PAD, both intermittent claudication and critical limb ischemia, and the promise of adeno-associated virus-based strategies delivering not just VEGFs (vascular endothelial growth factors) but a range of other mediators as potential new therapeutics. We also highlight challenges and failures in the clinical translation of gene therapy for PAD and how at least some of these obstacles may be overcome using adeno-associated virus.

Automated summary

Peripheral artery disease (PAD), caused by occlusive atherosclerosis, is a vascular disorder that leads to impaired blood flow in the lower extremities. With over 200 million affected individuals globally, PAD is an increasing global health problem due to aging population and rising diabetes incidence. Gene therapy offers potential to improve blood flow in PAD patients through angiogenesis and arteriogenesis. This article discusses gene therapy approaches for both intermittent claudication and critical limb ischemia in the context of PAD, as well as the use of adeno-associated virus-based strategies to deliver various mediators.